A Phase II Trial Evaluating Weekly Docetaxel and Capecitabine in Patients with Metastatic or Advanced, Locally Recurrent Head and Neck Cancers

REFERENCES

• American Cancer Society. Cancer Facts and Figures 2009.Washington, DC: American Cancer Society, Inc. 2009.
   Google Scholar
• Gibson, M.K.; Li, Y.; Murphy, B.; Hussain, M.H.; DeConti, R.C.; Ensley, J.; Forastiere, A.A.; Eastern Cooperative Oncology Group. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancers (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005, 23, 3562–3567.
   Google Scholar
• Forastiere, A.A.; Metch, B.; Schuller, D.E.; Ensley, J.F.; Hutchins, L.F.; Triozzi, P.; Kish, J.A.; McClure, S.; VonFeldt, E.; Williamson, S.K. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a southwest oncology group study. J Clin Oncol 1992, 10, 1245–1251.
   Google Scholar
• Jacobs, C.; Lyman, G.; Velez-García, E.; Sridhar, K.S.; Knight, W.; Hochster, H.; Goodnough, L.T.; Mortimer, J.E.; Einhorn, L.H.; Schacter, L. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992, 10, 257–263.
   PubMed Web of Science ®Google Scholar
• Inuyama, Y.; Kataura, A.; Togawa, K.; Saijo, S.; Satake, B.; Takeoda, S.; Konno, A.; Ebihara, S.; Sasaki, Y.; Kida, A.; Kanzaki, J.; Ichikawa, G.; Kono, N.; Moriyama, H.; Kamata, S.; Miyake, H.; Sakai, M.; Horiuchi, M.; Kubota, A.; Tsukuda, M.; Matsuura, H.; Baba, S.; Saito, H.; Matsunaga, T.; Taguchi, T. Late phase II clinical study of docetaxel in patients with advanced/recurrent head and neck cancers. Gan To Kagaku Ryoho 1999, 26, 107–116.
   PubMedGoogle Scholar
• Catimel, G.; Verweij, J.; Mattijssen, V.; Hanauske, A.; Piccart, M.; Wanders, J.; Franklin, H.; Le Bail, N.; Clavel, M.; Kaye, S.B. Docetaxel: an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994, 5, 553–537.
   PubMedGoogle Scholar
• Dreyfuss, A.I.; Clark, J.R.; Norris, C.M.; Rossi, R.M.; Lucarini, J.W.; Busse, P.M.; Poulin, M.D.; Thornhill, L.; Costello, R.; Posner, M.R. Docetaxel: an active drug against squamous cell carcinoma of the head and neck. J Clin Oncol 1996, 14, 1672–1678.
   PubMed Web of Science ®Google Scholar
• Couteau, C.; Chouaki, N.; Leyvraz, S.; Oulid-Aissa, D.; Lebecq, A.; Domenge, C.; Groult, V.; Bordessoule, S.; Janot, F.; De Forni, M.; Armand, J.P. A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer 1999, 81, 457–362.
   PubMed Web of Science ®Google Scholar
• Schoffski, P.; Wanders, J.; Verweij, J.; Fumoleau, P.; EORTC Early Clinical Studies Group. Docetaxel and cisplatin in head and neck cancers. Ann of Oncol 2000, 11, 1617.
   PubMed Web of Science ®Google Scholar
• Janinis, J.; Papadakou, M.; Xidakis, E.; Boukis, H.; Poulis, A.; Panagos, G.; Lefantzis, D. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent squamous cell carcinoma of the head and neck cancer: a phase II feasibility study. Amer J Clin Oncol 2000, 23, 128–131.
   PubMed Web of Science ®Google Scholar
• Sawada, N.; Ishikawa, T.; Fukase, Y.; Sawada, N.; Ishikawa, T.; Ishitsuka, H.; Tanaka, Y. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 1998, 4,1013–1009.
   PubMed Web of Science ®Google Scholar
• Fujimoto-Ouchi, K.; Tanaka, Y.; Tominaga, T. Schedule dependency of antitumor activity in combination therapy with capecitabine/5′-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin Cancer Res 2001, 7, 1079–1086.
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy, J.; Miles, D.; Vukelja, S.; Moiseyenko, V.; Ayoub, J.P.; Cervantes, G.; Fumoleau, P.; Jones, S.; Lui, W.Y.; Mauriac, L.; Twelves, C.; Van Hazel, G.; Verma, S.; Leonard, R. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002, 20, 2812–2823.
   PubMed Web of Science ®Google Scholar
• Mackey, J.R.; Tonkin, K.S.; Koski, S.L.; Scarfe, A.G.; Smylie, M.G.; Joy, A.A.; Au, H.J.; Bodnar, D.M.; Soulieres, D.; Smith, S.W. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer. Clin Breast Cancer 2004, 5, 287–292.
   PubMedGoogle Scholar
• Nadella, P.; Shapiro, C.; Otterson, G.A.; Hauger, M.; Erdal, S.; Kraut, E.; Clinton, S.; Shah, M.; Stanek, M.; Monk, P.; Villalona-Calero, M.A. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 2002, 20, 2616–2623.
   PubMed Web of Science ®Google Scholar
• Cassidy, J.; Twelves, C.; Cameron, D.; Steward, W.; O’ Byrne, K.; Jodrell, D.; Banken, L.; Goggin, T.; Jones, D.; Roos, B.; Bush, E.; Weidekamm, E.; Reigner, B. Bioequivalence to two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol 1999, 44, 453–460.
   PubMed Web of Science ®Google Scholar
• Fujii, H.; Sasaki, Y.; Ebihara, S.; Kida, Y.; Ichikawa, G.; Kaniyawa, S. An early phase II study of docetaxel (Taxotere) in patients with head and neck cancer. Proc Am Soc Clin Oncol 1995, 14, 298 (Abstr 859).
   Google Scholar
• Colevas, A.D.; Adak, S.; Amrein, P.C.; Barton, J.J.; Costello, R.; Posner, M.R. A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck. Annals of Oncology 2000, 11, 535–539.
   PubMed Web of Science ®Google Scholar
• Vermorken, J.B.; Mesia, R.; Rivera, F.; Remenar, E.; Kawecki, A.; Rottey, S.; Erfan, J.; Zabolotnyy, D.; Kienzer, H.R.; Cupissol, D.; Peyrade, F.; Benasso, M.; Vynnychenko, I.; De Raucourt, D.; Bokemeyer, C.; Schueler, A.; Amellal, N.; Hitt, R. Platinum-based chemotherapy plus cetuximab in head and neck cancers. N Engl J Med. 2008, 359, 1116–1127.
   PubMed Web of Science ®Google Scholar
• Vermorken, J.B.; Remenar, E.; van Herpen, C.; Gorlia, T.; Mesia, R.; Degardin, M.; Stewart, J.S.; Jelic, S.; Betka, J.; Preiss, J.H.; van den Weyngaert, D.; Awada, A.; Cupissol, D.; Kienzer, H.R.; Rey, A.; Desaunois, I.; Bernier, J.; Lefebvre, J.L.; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancers. N Engl J Med 2007, 357, 1695–1704.
   PubMed Web of Science ®Google Scholar
• Simon, R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10, 1–10.
   PubMedGoogle Scholar
• Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.; Wanders, J.; Kaplan, R.S.; Rubinstein, L.; Verweij, J.; Van Glabbeke, M.; van Oosterom, A.T.; Christian, M.C.; Gwyther, S.G. New guidelines to evaluate response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92, 205–216.
   PubMed Web of Science ®Google Scholar